RayKnowChina Research Map
Shortlist

Enrolling by invitationBreast cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

T-DM1 Combined With CDK4/6 Inhibitor Ribociclib

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Zhejiang Cancer Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Zhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06481956, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Patients who have developed other malignancies in the 5 years prior to screening, except adequately treated cervical cancer in situ, non-melanoma skin cancer, localized prostate cancer, ductal carcinoma in situ, or stage I uterine cancer.

    Exclusion criterion 4

  3. Received an investigational drug within 28 days prior to initiation of study therapy.

    Exclusion criterion 6

  4. The Physical status (ECOG) score of the Eastern Tumor Collaboration group was 0 or 1.

    Inclusion criterion 7

  5. The results of the serum pregnancy test were positive.

    Exclusion criterion 8

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06481956, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥18 at the time of signing the informed consent.
  • Patient's ability to follow the study protocol as determined by the investigator.
  • A representative tumor tissue sample is required to confirm a HER2-positive diagnosis.

HER2 expression status and ER expression status of invasive cancer lesions were determined based on previous pathological sections or current pre-treatment biopsy materials, and the HER2 IHC assay was locally confirmed to be consistent with 3+, or IHC assay with 2+, and further FISH detection was positive before study enrollment.

  • At least one evaluable lesion was detected by CT or MRI (see protocol for additional details).
  • For metastatic or recurrent breast cancer, there is currently no opportunity for surgical radical resection.
  • Metastatic or recurrent breast cancer that has received at least first-line rescue therapy in the past must have been treated with trastuzumab and taxanes.
  • The Physical status (ECOG) score of the Eastern Tumor Collaboration group was 0 or 1.
  • Sufficient haematology and organ function to meet the definition of laboratory test results, which must be provided within 14 days before the start of study therapy.
  • Fertile women should remain abstinent (no heterosexual intercourse) or use contraceptive methods.

Exclusion Criteria:

  • Past treatment with other antibody-drug conjugate (ADC) drugs or anti-tumor therapy with CDK4/6 inhibitors.
  • Past treatment with other anti-HER2 drugs other than trastuzumab, pertuzumab and tyrosine kinase inhibitors (TKI).
  • Advanced breast cancer with central nervous system metastasis.
  • Patients who have developed other malignancies in the 5 years prior to screening, except adequately treated cervical cancer in situ, non-melanoma skin cancer, localized prostate cancer, ductal carcinoma in situ, or stage I uterine cancer.
  • Severe dysfunction of vital organs prior to enrollment (see protocol details).
  • Received an investigational drug within 28 days prior to initiation of study therapy.
  • Known hypersensitivity or hypersensitivity to CDK4/6 inhibitors.
  • The results of the serum pregnancy test were positive.

Quoted from ClinicalTrials.gov, NCT06481956, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06481956, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06481956